Hexarelin

Hexarelin is a linear hexapeptide containing two D-amino-acid residues that confer enzymatic stability while retaining ghrelin-receptor affinity. The molecule's primary interaction in the published literature is agonism at the growth-hormone secretagogue receptor type 1a (GHS-R1a), engaging the same Gq/PLC signaling cascade documented for the endogenous ligand ghrelin and other GHRP-class compounds. A secondary interaction profile in cardiovascular-tissue research describes engagement with the CD36 scavenger receptor in a distinct signaling context. Pharmacokinetic descriptors documented in published animal-model investigations include rapid plasma clearance and a short-to-moderate systemic half-life under standard parenteral paradigms — somewhat longer than smaller GHRP-class peptides. All activity descriptors here are framed as documented in published work. Structural confirmation is established by mass spectrometry and HPLC-validated purity on each Certificate of Analysis.

Experimental domains documented in the published literature include GHS-R1a receptor-binding studies, comparative GHRP-class structure-activity investigations, somatotroph-cell calcium-signaling assays, CD36 scavenger-receptor engagement in cardiovascular-tissue research, and feedback-loop modeling in growth-hormone-axis paradigms. Investigators have also characterized Hexarelin in studies of receptor-internalization kinetics and in screening assays for GHS-R1a-active ligand discovery. Use in laboratory research extends to mechanism-elucidation paradigms where the molecule serves as a tool for parsing GHS-R1a from CD36-pathway signaling. The reference standard is supplied for these and equivalent in-vitro experimental contexts only, with no associated guidance for human, clinical, or veterinary application. Researchers should consult primary literature when designing context-specific protocols.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C47H58N12O6 empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human or veterinary application.